Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata

Study type: Clinical Trials Posting date: 05/26/2026 Last updated: 05/26/2026 Status: Active Phase: Phase 2 Country: USA and internationally Eligibility:

-Have severe (≥50% and ≤90% scalp hair loss) alopecia areata (AA)
-Agree not to use any AA treatments during the study
-Ages 18 to 50 years
-Have not received oral JAK Inhibitors in the past

*Other criteria will apply

Drug: LY4005130 Administration: IV Sponsor: Lilly Sponsor Link: Click here ClinicalTrials.gov link: Click here Location: Multiple locations

Description:

The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata when compared with placebo, and how well it’s tolerated and what side effects may occur. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.

The study drug will be administered intravenously (IV) (into a vein in the arm).

The study will last approximately 48 weeks, including screening.